Metformin Real-World Response Rate: What Patients Actually Experience

Is there a published real-world response rate for metformin?

No established metformin-specific percentage of patients reaching a target HbA1c in ordinary practice is available, and studies do not measure response the same way. A multicenter observational study of 1,657 patients on different oral antidiabetic regimens, including a metformin-alone group of 513 patients, reports a "response rate" of 75.5% in its abstract. It does not define that figure as reaching a glucose target, so it cannot be read as the share of people metformin works for [1]. Elsewhere the reported outcomes are mean glucose changes and drop-out rates.

Metformin is a biguanide prescribed for type 2 diabetes. The immediate-release label covers adults and children 10 years and older; the extended-release label covers adults [3][4]. Prediabetes, PCOS and weight loss are not labeled indications [3]. The labeled action is to lower basal and post-meal glucose by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity [3].

What the average HbA1c change looks like

A systematic review and meta-analysis of randomized trials in type 2 diabetes included 41 studies (3,074 patients) with blood pressure and/or lipid data, with metformin treatment lasting at least 6 weeks. Compared with control treatment, HbA1c was 0.74 percentage points lower on metformin (95% CI 0.65 to 0.84 lower; P<0.00001) [2]. The same analysis found significantly lower triglycerides, total cholesterol and LDL cholesterol with metformin, and no significant change in systolic or diastolic blood pressure or HDL cholesterol [2].

That 0.74-point figure is a group average against control, not a responder count. The label also states that clinical studies have not established conclusive evidence of macrovascular risk reduction with metformin [3].

How many people stop taking metformin?

Gastrointestinal effects dominate. In the label's US trial of immediate-release metformin at doses up to 2,550 mg a day (141 patients on metformin, 145 on placebo), diarrhea occurred in 53% versus 12%, nausea or vomiting in 26% versus 8%, and flatulence in 12% versus 6%; diarrhea led to discontinuation in 6% [3].

In placebo-controlled trials of extended-release metformin (781 patients on the drug, 195 on placebo), diarrhea occurred in 10% versus 3% and nausea or vomiting in 7% versus 2%; diarrhea led to discontinuation in 0.6% [4]. These are separate trials in separate patients, and the label cautions that adverse reaction rates from different trials cannot be compared directly [4].

A retrospective chart review looked at 310 patients on extended-release metformin and 158 on immediate-release metformin (mean daily doses about 1,258 mg and 1,282 mg). Roughly 25% of the extended-release group had been switched from the immediate-release form because of GI side effects, and the frequency of any GI adverse event was similar between the two formulations [7].

In the Diabetes Prevention Program, GI symptoms were more common with metformin than with placebo and declined over the follow-up, and no significant safety issues were identified [5].

Documented factors that differ between people

Drug transporter genetics. The OCT1 transporter plays a role in the uptake of metformin into liver cells. The reduced-function variant OCT1-420del has an allele frequency of roughly 20% in white Americans, and in clinical studies the effect of metformin in glucose tolerance tests was significantly lower in people carrying reduced-function OCT1 variants [8].

Adherence. In the DPP, the amount of weight lost during the 2-year double-blind phase was directly related to adherence (P<0.001) [5].

Kidney function limits who can take it. The label calls for checking eGFR before starting metformin and at least yearly afterward. It is contraindicated below 30 mL/min/1.73 m2, starting is not recommended when eGFR is 30 to 45, and benefit and risk are reassessed if eGFR later falls below 45 [3].

Does metformin prevent diabetes, and does the effect hold?

The Diabetes Prevention Program randomized 3,234 adults with elevated fasting and post-load glucose and no diabetes to placebo, metformin 850 mg twice daily, or an intensive lifestyle program. Over a mean 2.8 years, diabetes incidence was 11.0 cases per 100 person-years on placebo, 7.8 on metformin and 4.8 with lifestyle: a 31% reduction with metformin (95% CI 17 to 43%) and 58% with lifestyle. The number needed to treat for 3 years was 13.9 for metformin and 6.9 for lifestyle [6].

At 15 years, in a follow-up of 2,776 original participants, the metformin reduction had shrunk to 18% (HR 0.82) and lifestyle to 27% (HR 0.73). Cumulative incidence at 15 years was 56% on metformin, 55% with lifestyle and 62% on placebo, with no overall difference in microvascular disease (13.0% metformin, 12.4% placebo, 11.3% lifestyle) [9]. This is prevention in people who did not have diabetes, not a treatment response rate.

Weight and vitamin B12 over the long term

During the double-blind DPP, weight fell 2.06% with metformin and 0.02% with placebo, and waist circumference fell 2.13 cm versus 0.79 cm; across 7 to 8 further years of open-label follow-up the metformin group held a 2.0% loss versus 0.2% [5]. A meta-analysis of randomized trials associated metformin with 1.1 kg of weight loss [10]. Among 1,066 DPP participants who lost at least 5% of baseline weight in the first year, maintained loss between years 6 and 15 was 6.2% with metformin, 3.7% with lifestyle and 2.8% with placebo, a post hoc analysis of non-randomized subsets [11]. After 1 year, 28.5% of the metformin group and 13.4% of the placebo group had lost at least 5% of baseline body weight [11].

On B12, the label reports subnormal levels in approximately 7% of patients in 29-week clinical trials, and says hematologic parameters should be measured annually and vitamin B12 every 2 to 3 years [3]. In the DPP follow-up, low B12 (203 pg/mL or less) occurred in 4.3% of metformin users versus 2.3% of placebo at 5 years, and 7.4% versus 5.4% at 13 years; low plus borderline-low B12 (298 pg/mL or less) was 19.1% versus 9.5% at 5 years [12]. The odds of deficiency rose 13% per year of metformin use (OR 1.13, 95% CI 1.06 to 1.20) [12].

HealthRX.com offers metformin by prescription.